

1644
DPA

<p style="text-align: center;">TRANSMITTAL FORM</p> <p style="text-align: center;">MAY 22 2006</p> <p style="text-align: center;">(to be used for all correspondence after initial filing)</p>		Application Number	10/516,837
		Filing Date	August 9, 2005
		First Named Inventor	Robert Paul Anderson
		Art Unit	1644
		Examiner Name	Sanjoo Jalla
Total Number of Pages in This Submission		Attorney Docket Number	BTG0008-101 (144404US01)

ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached/Authorized <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Forms PTO SB/08a and SB/08b (8 pp.); (101) References Cited, (79) References Enclosed.

Remarks**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm	Cozen O'Connor		
Signature			
Printed Name	Paul K. Legaard, Ph.D.		
Date	18 MAY 2006	Reg. No.	38,534

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature	
Typed or printed name	Paul K. Legaard, Ph.D., Registration No. 38,534
	Date 18 MAY 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



BTG0008-101 (144404US01)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 22 2006

In re application of: **Anderson, Hill and Jewell**

Serial No.: **10/516,837**

Group Art Unit: **1644**


Filing Date: **August 9, 2005**

Examiner: **Sanjoo Jalla**

For: **Therapeutic Epitopes and Uses Thereof**

I certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA, 22313-1450.

On 18 May 2006


Paul K. Legaard, Ph.D., Registration No. 38,534

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed:

- within three months of the filing date of the patent application.
- within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
- before the mailing date of a first Office Action on the merits.

- after the mailing date of a first Office Action on the merits, but before the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:
 - the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);
or
 - the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or
 - No fee is owed by the applicant(s).
- In accordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is being filed in connection with the first or second After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.
- after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), (see "Statement," and "Fees" below).
- Copies of the references (except the U.S. Patent documents) listed on the attached PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449 are enclosed.

EXCEPT THAT:

- In view of the voluminous nature of references **CR and CS**, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- In accordance with 37 C.F.R. § 1.98(d), copies of the references A-J listed on the attached PTO Form SB/08A, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) _____ for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.
- If the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Statement under 37 C.F.R. § 1.97(e)

The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

Fees

No Fee is owed by the applicant(s).

The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.

Method of Payment of Fees

Attached is a check in the amount of \$_____ . This form is submitted in duplicate.

Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.

Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.

No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,



Paul K. Legaard, Ph.D.
Registration No. 38,534

Dated: 18 May 2006

COZEN O'CONNOR, P.C.
1900 Market Street, 5th Floor
Philadelphia, PA 19103-3508
(215) 665-2000 – Telephone
(215) 701-2013 - Facsimile



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

8

Complete if Known

Application Number	10/516,837
Filing Date	August 9, 2005
First Named Inventor	Robert Paul Anderson
Art Unit	1644
Examiner Name	Sanjoo Jalla

Attorney Docket Number

BTG0008-101

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
AA	US-4,459,355		07-10-1984	Cello et al.	
AB	US-4,536,475		08-20-1985	Anderson	
AC	US-5,464,763		11-07-1995	Schilperoort et al.	
AD	US-5,177,010		01-05-1993	Goldman et al.	
AE	US-5,187,073		02-16-1993	Goldman et al.	
AF	US-4,945,050		07-31-1990	Sanford et al.	
AG	US-5,036,006		07-30-1991	Sanford et al.	
AH	US-5,100,792		03-31-1992	Sanford et al.	
AI	US-5,371,014		12-06-1994	Matsuyama et al.	
AJ	US-5,478,744		12-26-1995	Sanford et al.	
AK	US-5,179,022		01-12-1993	Sanford et al.	
AL	US-5,565,346		10-15-1996	Facciotti	
AM	US-5,484,956		01-16-1996	Lundquist et al.	
AN	US-5,508,468		04-16-1996	Lundquist et al.	
AO	US-5,538,877		07-23-1996	Lundquist et al.	
AP	US-5,554,798		09-10-1996	Lundquist et al.	
AQ	US-5,489,520		02-06-1996	Adams et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
AR		EP 0255378	02-03-1988	Calgene		
AS		WO 92/17580	10-15-1992	Rhone-Poulenc		
AT		WO 98/45460	10-15-1998	Rhone-Poulenc		
AU		WO 98/45461	10-15-1998	Rhone-Poulenc		
AV		EP 267159	05-11-1988	Ciba-Geigy		
AW		EP 604662	07-06-1994	Japan Tobacco		
AX		EP 672752	09-20-1995	Japan Tobacco		
AY		EP 442174	08-21-1991	Pioneer Hi-Bred		
AZ		EP 486233	05-20-1992	Pioneer Hi-Bred		


Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

~~Substitute for form 1449A/PTO~~

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Shee

of

Complete if Known

<i>Application Number</i>	10/516,837
<i>Filing Date</i>	August 9, 2005
<i>First Named Inventor</i>	Robert Paul Anderson
<i>Art Unit</i>	1644
<i>Examiner Name</i>	Sanjoo Jalla
<i>Attorney Docket Number</i>	BTG0008-101

Attorney Docket Number **BTG0008**

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date/Filing Date MM-DD-YYYY			
	BD	EP486234	05-20-1992	Pioneer Hi-Bred		
	BE	EP 539563	10-17-2001	Monsanto		
	BF	WO 94/13863	06-23-1994	Amorphous		
	BG	WO 91/02071	02-21-1991	DeKalb Plant Genetics		
	BH	WO 95/06128	03-02-1995	Dekalb Genetics		
	BI	EP 0293358	11-30-1988	Monsanto Co		
	BJ	WO 92/000377	01-09-1992	Monsanto Co		
	BK	EP 0242236	10-21-1987	Plant Genetics Systems		
	BL	EP 0369367	05-23-1990	Lincoln Electric		

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



MAY 22 2008

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 2055-0231

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

She

1

10

Complete if Known

<i>Application Number</i>	10/516,837
<i>Filing Date</i>	August 9, 2005
<i>First Named Inventor</i>	Robert Paul Anderson
<i>Art Unit</i>	1644
<i>Examiner Name</i>	Sanjoo Jalla
<i>Attorney Docket Number</i>	BTG0008-101

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	BM	WO 03/104273	12-18-2003	ISIS Innovation		
	BN	WO 02/083722	10-24-2002	Koning		
	BO	WO 03/066079	08-14-2003	Koning		
	BP	WO 03/096984	11-27-2003	Hausch		
	BQ	WO 98/23960	06-04-1998	ISIS Innovation		
	BR	WO 92/20809	11-26-1992	Agracetus		
	BS	WO 99/20775	04-29-1999	Rhone-Poulenc		
	BT	EP 0693119	01-29-1997	Oxford Biosciences		
	BU	EP 0905518	03-31-1999	Konig		
	DW	WO 01/25793	04-12-2001	ISIS Innovation		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

8

Complete if Known

Application Number	10/516,837
Filing Date	August 9, 2005
First Named Inventor	Robert Paul Anderson
Art Unit	1644
Examiner Name	Sanjoo Jalla

Attorney Docket Number

BTG0008-101

NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BV	Altschul "A protein alignment scoring system sensitive at all evolutionary distances," <i>J Mol Evol</i> (1993) 36(3):290-300.	
	BW	Altschul et al., "Basic local alignment search tool," <i>J Mol Biol</i> (1990) 215(3):403-410.	
	BX	Bunce et al., "Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP)," <i>Tissue Antigens</i> (1995) 46(5):355-367.	
	BY	Dalta et al., "Plant promoters for transgene expression," <i>Biotechnology Ann Rev</i> (1997) 3:269-296.	
	BZ	Devereux et al., "A comprehensive set of sequence analysis programs for the VAX," <i>Nucleic Acids Research</i> (1984) 12(1 Pt 1):387-395.	
	CA	Greenberg et al., "Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues," <i>FASEB</i> (1991) 5(15):3071-3077.	
	CB	Henikoff "Amino acid substitution matrices from protein blocks," <i>Proc. Natl. Acad Sci USA</i> (1992) 89(22):10915-10919.	
	CC	Karlin et al., "Applications and statistics for multiple high-scoring segments in molecular sequences," <i>Proc Natl Acad USA</i> (1993) 90(12):5873-5887.	
	CD	Kohler et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> (1975) 256(5517):495-497.	
	CE	Kricka "Prospects for chemiluminescent and bioluminescent immunoassay and nucleic acid assays in food testing and the pharmaceutical industry," <i>J Biolumin Chemilumin</i> (1998) 13(4):189-193.	
	CF	Lalvani et al., "Rapid effector function in CD8+ memory T cells," <i>J Exp Med</i> (1997) 186(6):859-865.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

5

of

8

Complete if Known

Application Number	10/516,837
Filing Date	August 9, 2005
First Named Inventor	Robert Paul Anderson
Art Unit	1644
Examiner Name	Sanjoo Jalla
Attorney Docket Number	BTG0008-101

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CG	Mantzaris et al., "In vivo toxicity of a synthetic dodecapeptide from A gliadin in patients with coeliac disease," <i>Gastroenterol.</i> (1991) 26(4):392-398.	
	CH	Maiuri et al., "In vitro activities of A-gliadin-related synthetic peptides: damaging effect on the atrophic coeliac mucosa and activation of mucosal immune response in the treated coeliac mucosa," <i>Scand J Gastroenterol.</i> (1996) 31(3):247-253.	
	CI	Molberg et al., "Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease," <i>Nature Med</i> (1998) 4(6):713-717.	
	CJ	Mullighan et al., "High-resolution HLA-DQB1 typing using the polymerase chain reaction and sequence-specific primers," <i>Tissue Antigens</i> (1997) 50(6):688-692.	
	CK	Olerup et al., "HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours," <i>Tissue Antigens</i> (1993) 41(3):119-137.	
	CL	Ota et al., "T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis," <i>Nature</i> (1990) 346(6280):183-187.	
	CM	Quarsten et al., "HLA binding and T cell recognition of a tissue transglutaminase-modified gliadin epitope," <i>Eur J Immunol</i> (1999) 29(8):2506-2514.	
	CN	Thurau et al., "Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals," <i>Clin Exp Immunol</i> (1997) 109(2):370-376.	
	CO	Vasil et al., "Herbicide Resistant Fertile Transgenic Wheat Plants Obtained by Microprojectile Bombardment of Regenerable Embryogenic Callus," <i>Biotechnology</i> (1992) 10:667-674.	
	CP	Weiner et al., "Oral tolerance: cytokine milieu in the gut and modulation of tolerance by cytokines," <i>Res Immunol</i> (1997) 148(8-9):528-533.	
	CQ	Yoshida et al., "The oral administration of low-dose antigen induces activation followed by tolerization, while high-dose antigen induces tolerance without activation," <i>Clin Immunol Immunopathol</i> (1997) 82:207-215.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

6

of

8

Complete if Known

Application Number	10/516,837
Filing Date	August 9, 2005
First Named Inventor	Robert Paul Anderson
Art Unit	1644
Examiner Name	Sanjoo Jalla

Attorney Docket Number

BTG0008-101

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CR*	Sambrook et al., <i>Molecular Cloning: A Laboratory Manual</i> (1989).	
	CS*	Vader et al., <i>Proceedings 8th International Symposium Coeliac Disease</i> .	
	CT	Anderson "Identification of the Immunodominant T-Cell Epitope in Agliadin Recognized by Coeliac Disease (CD) Patients in Vivo," (1999) A165.	
	CU	Dieterich et al., "Identification of tissue transglutaminase as the autoantigen of celiac disease," <i>Nature Medicine</i> (1997) 3(7):797-801.	
	CV	Gutgemann et al., "Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen," <i>Immunity</i> (1998) 8:667-673.	
	CW	McAdam et al., "Gliadin Specific Response by Small Intestinal T Cells," <i>Peptide Binding to HLA Molecules and T Cells</i> , Eighth International Symposium on Coeliac Disease, p. 17, (1999).	
	CX	Sjostrom et al., "Identification of a gliadin T-cell epitope in coeliac disease: general importance of gliadin deamidation for intestinal T-cell recognition," <i>Scand J Immunol</i> (1998) 48(2):111-115.	
	CY	Tian et al., "Antigen-based immunotherapy for autoimmune disease: from animal models to humans?" <i>Immunology Today</i> (1999) 20(4):190-195.	
	CZ	Van de Wal et al., "Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity," <i>The Journal of Immunology</i> (1998) 161(4):1585-1588.	
	DA	Arentz-Hansen et al., "Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues," <i>Gastroenterology</i> (2002) 123(3):803-809.	
	DB	Jung et al., "From combinatorial libraries to MHC ligand motifs, T-cell superagonists and antagonists," <i>Biologicals</i> (2001) 29(3-4):179-181.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

MAY 22 2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

7

of

8

Complete if Known

Application Number	10/516,837
Filing Date	August 9, 2005
First Named Inventor	Robert Paul Anderson
Art Unit	1644
Examiner Name	Sanjoo Jalla

Attorney Docket Number

BTG0008-101

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	DC	Mowat et al., "Coeliac disease--a future for peptide therapy?," <i>Lancet</i> (2000) 356(9226):270-271.	
	DD	Madsen et al., "A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor," <i>Nature Genetics</i> (1999) 23(3):343-347.	
	DE	Van de Wal et al., "Coeliac disease: it takes three to tango!," <i>Gut</i> (2000) 46(5):734-737.	
	DF	Vader et al., "Specificity of Tissue Transglutaminase Explains Cereal Toxicity in Celiac Disease," <i>Journal of Experimental Medicine</i> (2002) 195(5):643-649.	
	DG	Wieser et al., "Coeliac active peptides from gliadin: large-scale preparation and characterization," <i>Z Lebensm Unters Forsch</i> (1992) 194(3):229-234.	
	DH	Kumar et al., "Human genome search in celiac disease: mutated gliadin T-cell-like epitope in two human proteins promotes T-cell activation," <i>Journal of Molecular Biology</i> (2002) 319(3):579-599.	
	DI	Moustakas et al., "Structure of celiac disease-associated HLA-DQ8 and non-associated HLA-DQ9 alleles in complex with two disease-specific epitopes," <i>International Immunology</i> (2000) 12(8):1157-1166.	
	DJ	Piper et al., "High Selectivity of Human Tissue Transglutaminase for Immunoactive Gliadin Peptides: Implications for Celiac Sprue," <i>Biochemistry</i> (2002) 41(1):386-393.	
	DK	Plebanski et al., "Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use," <i>Eur J Immunol</i> (1998) 28(12):4345-4355.	
	DL	Anderson et al., "The α -gliadin gene family. II. DNA and protein sequence variation, subfamily structure, and origins of pseudogenes," <i>Theor Appl Genet</i> (1997) 95:59-65.	
	DM	Vader et al., "The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides," <i>Gastroenterology</i> (2002) 122:1729-1737.	


Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

8

of

8

Complete if Known

Application Number	10/516,837
Filing Date	August 9, 2005
First Named Inventor	Robert Paul Anderson
Art Unit	1644
Examiner Name	Sanjoo Jalla

Attorney Docket Number

BTG0008-101

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	DN	ARENTZ-HANSEN, Helene; The Intestinal T Cell Response to α -Gliadin in Adult Celiac Disease is Focused on a Single Deamidated Glutamine targeted by Tissue Transglutaminase; <i>J. Exp. Med.</i> Volume 191, No. 4, 2-200- 603-612.	
	DO	ANDERSON, Robert et al.; <i>in vivo</i> antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant α -gliadin T-cell epitope; <i>Nature Medicine</i> Vol. 6, No. 3, March 2000; 337-342.	
	DP	UHLIG, H. et al., Role of Tissue Transglutaminase in Gliadin Binding to Reticular Extracellular Matrix and Relation to Coeliac Disease Autoantibodies; <i>Autoimmunity</i> , Vol. 28, pp. 185-195.	
	DQ	Database SwissProt Online! ID: GDA4-Wheat ACC:P04724, 13 August 1987 (Abstract)	
	DR	OKITA, T. et al., Evolution and Heterogeneity of the α -1 β -type and Y-type Gliadin DNA Sequences; <i>The Journal of Biological Chemistry</i> ; Vol. 260, No. 13, July 5, 1985; pp. 8203-8213.	
	DS	GODKIN, A.S. et al., Identification of Coeliac Disease-Specific T Cell Epitope from A-Gliadin; <i>Gut</i> ; Vol. 44, Suppl. 1, page A72, April 1999.	
	DT	TRONCONE, R. et al., Cytokines produced by Gliadin-Specific T Cell Clones from the Coeliac Mucosa; <i>Gastroenterology</i> , Vol. 110, No. 4, p. A103, April 1996.	
	DU	VAN DE WAL, Y et al., Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin; <i>Proc. Natl. Acad. Sci.</i> Vol. 95, pp. 10050-10054, August 1998; <i>Immunology</i> .	
	DV	O'KEEFFE, J. et al. T cell proliferation, MHC class II restriction and cytokine products of gliadin-stimulated peripheral blood mononuclear cells (PBMC); <i>Clin. Exp. Immunol.</i> ; 1999; 117:269-276.	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.